2nd Quarter - Report

BOSTON SCIENTIFIC CORPORATION for BOSTON SCIENTIFIC CORPORATION

Firm
Client
Income
—
Expenses
$480,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

8 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

H.R. 422, a bill to permanently extend and strengthen the federal R & D tax credit S.1203, the GROWTH Act, a bill to extend the research credit through 2010 and to increase and make permanent the alternative simplified research credit Deferral tax as mentioned in the President's proposed budget for 2010 and as a proposed payment for health reform

LobbyistCovered position, as disclosed
BRENDA BECKER —
JEAN CECIL FRICK —
STEVEN NEIL LAPIERRE —
MICHAEL MATTOON —

Contacted: Office of Management & Budget (OMB); U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); State, Dept of (DOS); Food & Drug Administration (FDA); Congressional Budget Office (CBO); Medicare Payment Advisory Commission (MedPAC); Government Accountability Office (GAO); SENATE; Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES

Bills named: S. 1203 (111th), H.R. 422 (111th)

Health Issues HCR

Senate and House Committee Health Reform bills with an emphasis on physician disclosure, comparative effectiveness research, pain research, bundling and gainsharing S.540, Medical Device Safety Act, a bill that would remove federal preemption protection for certain medical devices H.R.1346, Medical Device Safety Act, a bill that would remove federal preemption protection for certain medical devices Reform of the 510 (k) regulatory pathway H.R. 759, Food and Drug Administration Globalization Act, a bill to improve the safety of food, drugs, devices, and cosmetics S. 882, the Drug and Device Accountability Act, a bill to ensure the safety and quality of medical products and enhance the authorities of the FDA H.R. 2502, Comparative Effectiveness Research Act of 2009, a bill to provide for the conduct of comparative effectiveness research and create a Comparative Effectiveness Research Trust Fund S.1213, Patient-Centered Outcomes Research Act of 2009, a bill to provide for the conduct of comparative effectiveness research and to establish a Patient-Centered Outcomes Research Trust Fund H.R. 2824, Doctor-Patient Relationship and Research Protection Act, a bill to support federally funded comparative effectiveness research relating to health care S.1142, Informed Health Care Decision Making Act, a bill with respect to the inclusion of effectiveness information in drug and device labeling and advertising

LobbyistCovered position, as disclosed
BRENDA BECKER —
JEAN CECIL FRICK —
STEVEN NEIL LAPIERRE —
MICHAEL MATTOON —
SCOTT REID —

Contacted: SENATE; Government Accountability Office (GAO); Congressional Budget Office (CBO); U.S. Trade Representative (USTR); Medicare Payment Advisory Commission (MedPAC); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS)

Bills named: S. 1142 (111th), H.R. 1346 (111th), H.R. 759 (111th), S. 540 (111th), S. 882 (111th), S. 1213 (111th), H.R. 2824 (111th), H.R. 2502 (111th)

Medicare/Medicaid MMM

S.660, National Pain Care Policy Act, a bill to promote greater access to chronic pain therapies H.R. 756, National Pain Care Policy Act, a bill to promote greater access to chronic pain therapies S.1380, Medicare Payment Advisory Commission (MedPAC) Reform Act , a bill to make the commission an executive branch agency, and provide the Commission new resources and authority to implement Medicare payment policy S.301, Physician Payments Sunshine Act, a bill that would require disclosure of the relationships between physicians and the manufacturers of drugs and devices H.R. 3138, Physician Payments Sunshine Act, a bill that would require disclosure of the relationships between physicians and the manufacturers of drugs and devices H.R. 2502, Comparative Effectiveness Research Act of 2009, a bill to provide for the conduct of comparative effectiveness research and create a Comparative Effectiveness Research Trust Fund S.1213, Patient-Centered Outcomes Research Act of 2009, a bill to provide for the conduct of comparative effectiveness research and to establish a Patient-Centered Outcomes Research Trust Fund H.R. 2824, Doctor-Patient Relationship and Research Protection Act, a bill to support federally funded comparative effectiveness research relating to health care S.1142, Informed Health Care Decision Making Act, a bill with respect to the inclusion of effectiveness information in drug and device labeling and advertising Medicare coverage of PLATINUM clinical trial

LobbyistCovered position, as disclosed
BRENDA BECKER —
STEVEN NEIL LAPIERRE —
MICHAEL MATTOON —
SCOTT REID —

Contacted: SENATE; Health & Human Services, Dept of (HHS); State, Dept of (DOS); U.S. Trade Representative (USTR); Medicare Payment Advisory Commission (MedPAC); Commerce, Dept of (DOC); Congressional Budget Office (CBO); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Government Accountability Office (GAO); Office of Management & Budget (OMB)

Bills named: H.R. 2502 (111th), S. 1142 (111th), S. 1380 (111th), H.R. 3138 (111th), S. 660 (111th), H.R. 756 (111th), S. 301 (111th), H.R. 2824 (111th), S. 1213 (111th)

Labor Issues/Antitrust/Workplace LBR

S.560, the Employee Free Choice Act, a bill to establish an efficient system to enable employees to form, join, or assist labor organizations and to provide for mandatory injunctions for unfair labor practices during the organizing efforts H.R. 1409, the Employee Free Choice Act, a bill to establish an efficient system to enable employees to form, join, assist labor organizations, and to provide for mandatory injunctions for unfair labor practices during the organizing efforts

LobbyistCovered position, as disclosed
BRENDA BECKER —
JEAN CECIL FRICK —
STEVEN NEIL LAPIERRE —
MICHAEL MATTOON —

Contacted: Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); SENATE; Government Accountability Office (GAO); State, Dept of (DOS); HOUSE OF REPRESENTATIVES; Congressional Budget Office (CBO); Commerce, Dept of (DOC); Office of Management & Budget (OMB); Food & Drug Administration (FDA); Medicare Payment Advisory Commission (MedPAC); Health & Human Services, Dept of (HHS)

Bills named: H.R. 1409 (111th), S. 560 (111th)

Natural Resources NAT

HR. 2454, American Clean Energy and Security Act, a bill to create clean energy jobs, achieve energy independence, reduce global warming pollution and transition to a clean energy economy S.5 a bill to reduce the dependence on foreign and unsustainable energy sources and risks of global warming

LobbyistCovered position, as disclosed
BRENDA BECKER —
STEVEN NEIL LAPIERRE —
MICHAEL MATTOON —

Contacted: Medicare Payment Advisory Commission (MedPAC); Food & Drug Administration (FDA); Congressional Budget Office (CBO); Health & Human Services, Dept of (HHS); State, Dept of (DOS); SENATE; HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Government Accountability Office (GAO)

Bills named: H.R. 2454 (111th), S. 5 (111th)

Financial Institutions/Investments/Securities FIN

Over the Counter Derivatives, provisions related to changing the regulation

LobbyistCovered position, as disclosed
BRENDA BECKER —
STEVEN NEIL LAPIERRE —
MICHAEL MATTOON —

Contacted: Food & Drug Administration (FDA); Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Office of Management & Budget (OMB); SENATE; Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); State, Dept of (DOS); Health & Human Services, Dept of (HHS); Congressional Budget Office (CBO); Government Accountability Office (GAO)

Copyright/Patent/Trademark CPT

S.515. Patent Reform Act of 2009, provisions related specifically to innovative technologies H.R. 1260, Patent Reform Act of 2009, provisions related specifically to innovative technologies

LobbyistCovered position, as disclosed
BRENDA BECKER —
STEVEN NEIL LAPIERRE —
MICHAEL MATTOON —

Contacted: Medicare Payment Advisory Commission (MedPAC); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; SENATE; Congressional Budget Office (CBO); Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); State, Dept of (DOS); U.S. Trade Representative (USTR); Food & Drug Administration (FDA); Government Accountability Office (GAO)

Bills named: S. 515 (111th), H.R. 1260 (111th)

Trade (domestic/foreign) TRD

Market Access, regulatory approvals and reimbursement for medical devices in Japan, EU, Korea, China, Brazil Trade agreements with Columbia and South Korea

LobbyistCovered position, as disclosed
BRENDA BECKER —
STEVEN NEIL LAPIERRE —
MICHAEL MATTOON —

Contacted: HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); SENATE; Government Accountability Office (GAO); Food & Drug Administration (FDA); State, Dept of (DOS); Congressional Budget Office (CBO); U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); Medicare Payment Advisory Commission (MedPAC)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.